International outsourcing of clinical trials to all parts of the globe
is no longer a new phenomenon in the biopharmaceutical industry. Among
emerging Asian markets, South
Korea is quickly becoming a dominant
outsourcing location for clinical trials. This is mostly due to a quickly
evolving regulatory environment, streamlined regulatory approval, reduced costs, and more successful patient
recruitment relative to many developed Western countries.
recently published an article entitled "Korea Path" (pp 30-36) which discusses the country's
current clinical research environment, including the challenges that must be
addressed by foreign companies.
What are the translation requirements? How do
cultural differences affect medical practices? What is the current regulatory
language service provider for over fifteen years, we are well aware of the
importance of native language communication, especially in the translation of
clinical trial documents. Our life science experts have translation experience
in over one hundred languages, including Korean, and other
dominant Asian languages.
Since we are continually learning about the industry, I am
interested in hearing your opinion about this topic and about cultural and
linguistic issues as they apply to companies interested in outsourcing.